‘‘Observable entity’ and ‘property type’ some ‘Susceptibility’ and ‘towards’ some <LOINC.component> and ‘technique’ some <LOINC.method> and ‘scale’ some <LOINC.scale> ‘time aspect’ some ‘Single point in time” ‘inheres in’ some ‘Microorganism’ and 'Direct site = 119303007 | Microbial isolate specimen (specimen) |'
In mapping ‘towards’ some <LOINC.component>:
1) We have mapped the LOINC parts containing one antibiotic to the equivalent substance
LP28719-0 1 Gatifloxacin (Mapped to: 116349004 Gatifloxacin (substance)) LP33354-9 1 Daptomycin (Mapped to: 406439009 Daptomycin (substance))
Combined substances added to the Substance hierarchy must meet the following criteria:
The physiologic or biologic action of the combination must be enhanced or synergistic
Combinations that do not have an enhanced or synergistic effect (e.g. combinations created for convenience) are out of scope.
Examples of combined substances that are in scope include:Ampicillin + sulbactamPiperacillin + tazobactam
Examples:
LP15937-3 1 Ampicillin+Sulbactam (Mapped to: 703744001 | Ampicillin and sulbactam (substance) |. A product concept also exist: 398786001 Product containing ampicillin and sulbactam (medicinal product))
LP29104-4 1 Quinupristin+Dalfopristin (No susbtance concept created yet. Product concept: 324352008 Product containing dalfopristin and quinupristin (medicinal product))
3) LOINC terms with an antibiotic component with strength specified: